Taiwan’s neuroendoscopes market is witnessing growth driven by the rising prevalence of neurological disorders, and an aging population along with the increasing adoption of advanced minimally invasive neurosurgical technologies across healthcare systems. Against this backdrop, the neuroendoscopes market in Taiwan is projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2036, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s latest report, “Neuroendoscopes Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals that Taiwan accounted for nearly 3% of the APAC neuroendoscopes market in 2025.

Aakansha Pankaj, Medical Devices Analyst at GlobalData, comments: “Within Asia-Pacific, larger markets Japan and China account for a substantial share of neuroendoscope demand, while Taiwan remains comparatively smaller and concentrated in tertiary referral centers. In Taiwan, adoption is expected to remain specialized and procurement-led, with growth tied to gradual upgrades to high-definition endoscopic visualization and minimally invasive neurosurgical workflows. However, the high capital and servicing costs of imported reusable systems can constrain wider penetration beyond leading institutions, potentially sustaining a center-of-excellence–driven adoption pattern.”

Brain Navi Biotechnology’s single-use 3D neuroendoscope “KrystoLens” has recently received certification from the Taiwan Food and Drug Administration (TFDA). Although physically a rigid system, this single-use scope is said to improve procedural and scheduling flexibility by eliminating the lengthy sterilisation and reprocessing workflows required for reusable devices.

By resolving these turnaround bottlenecks, the sterile, disposable format can increase immediate operational readiness in operating rooms, allowing healthcare facilities to transition from capital expenditure to a more predictable, cost-per-procedure model.

Pankaj concludes: “Expanding access to the emerging platform options such as higher-definition imaging and alternative procurement models beyond tertiary hospitals will be central to the broader uptake in Taiwan. Ultimately, commercial adoption will hinge on clinical familiarity and hospital procurement decisions and will likely be driven by demonstrated workflow benefits in active surgical settings, compelling total cost-of-ownership economics, and strong local clinical evidence supported by effective distribution partnerships.”